Facts and hopes in multiple myeloma immunotherapy
AS Sperling, KC Anderson - Clinical Cancer Research, 2021 - AACR
AS Sperling, KC Anderson
Clinical Cancer Research, 2021•AACRAmong the hallmarks of cancer is the ability of neoplastic cells to evade and suppress
immune surveillance to allow their growth and evolution. Nowhere is this as apparent as in
multiple myeloma, a cancer of antibody-producing plasma cells, where a complex interplay
between neoplastic cells and the immune microenvironment is required for the development
and progression of disease. Decades of research has led to the discovery of a number of
therapeutic agents, from cytotoxic drugs to genetically engineered cells that mediate their …
immune surveillance to allow their growth and evolution. Nowhere is this as apparent as in
multiple myeloma, a cancer of antibody-producing plasma cells, where a complex interplay
between neoplastic cells and the immune microenvironment is required for the development
and progression of disease. Decades of research has led to the discovery of a number of
therapeutic agents, from cytotoxic drugs to genetically engineered cells that mediate their …
Abstract
Among the hallmarks of cancer is the ability of neoplastic cells to evade and suppress immune surveillance to allow their growth and evolution. Nowhere is this as apparent as in multiple myeloma, a cancer of antibody-producing plasma cells, where a complex interplay between neoplastic cells and the immune microenvironment is required for the development and progression of disease. Decades of research has led to the discovery of a number of therapeutic agents, from cytotoxic drugs to genetically engineered cells that mediate their antimyeloma effects at least partially through altering these immune interactions. In this review, we discuss the history of immunotherapy and current practices in multiple myeloma, as well as the advances that promise to one day offer a cure for this deadly disease.
AACR